Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 6/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.36 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526207 | 0.87 | THRB (0.48) | HPRT1POLBTDP1ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7571975 | 0.82 | HDAC3 (0.48) | HPRT1POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL930873 | 0.82 | HPRT1 (0.47) | HPRT1POLBTDP1ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6935179 | 0.81 | HPRT1 (0.46) | HPRT1POLBTDP1ALDH1A1HPGD | |
| Water SCHEMBL6931313 | 0.81 | HPRT1 (0.46) | HPRT1POLBTDP1ALDH1A1HPGD | |
| SCHEMBL10506681 | 0.80 | HPRT1 (0.48) | HPRT1TYMS | |
| SCHEMBL5250159 | 0.79 | HPRT1 (0.60) | HPRT1 | |
| SCHEMBL7567089 | 0.78 | HPRT1 (0.54) | HPRT1 | |
| SCHEMBL7570074 | 0.77 | HPRT1 (0.53) | HPRT1ALDH1A1HPGDKMT2A | |
| SCHEMBL7570941 | 0.76 | HPRT1 (0.49) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001028545-A9 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1225877-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | Neotherapeutics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-6338963-B1 | GENE EXPRESSION OF MOLECULES IN MAMMALS | NEOTHERAPEUTICS, INC. | 2002-01-15 | — | — | US | claimed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | claimed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-6630490-B2 | Purine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001028545-A9 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS INC (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1225877-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | Neotherapeutics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | EVE M. TAYLOR | 2002-07-11 | — | — | US | disclosed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6338963-B1 | GENE EXPRESSION OF MOLECULES IN MAMMALS | NEOTHERAPEUTICS, INC. | 2002-01-15 | — | — | US | disclosed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | TYMP, TYMS, NGF | HPRT1 33/4885TYMS 2/4885POLB 161/4885 |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | NGF, NUDT1, HPRT1 | HPRT1 3/4885TYMS 19/4885POLB 511/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | HPRT1 42/4885TYMS 57/4885POLB 739/4885 |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | HPRT1 8/4885TYMS 87/4885POLB 773/4885 |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | DCX, MKI67, TK2 | HPRT1 825/4885TYMS 67/4885POLB 3648/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | HPRT1 10/4885TYMS 211/4885POLB 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.